Bolt Biotherapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase...
February 09 2021 - 4:05PM
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage
immuno-oncology company, announced today the closing of its initial
public offering of 13,225,000 shares of its common stock, inclusive
of the full exercise by the underwriters of their option to
purchase 1,725,000 shares of common stock, at a price to the public
of $20.00 per share. The shares are listed for trading on The
Nasdaq Global Select Market under the ticker symbol “BOLT”.
Morgan Stanley, SVB
Leerink, Stifel and Guggenheim Securities acted as joint
bookrunners for the offering.
The offering was made
only by means of a prospectus. Copies of the final prospectus
relating to the offering may be obtained from Morgan Stanley &
Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd
Floor, New York, NY 10014, or by email at
prospectus@morganstanley.com; or SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, or by telephone at (800) 808-7525, ext. 6105 or by email at
syndicate@svbleerink.com.
Registration
statements relating to these securities have been filed with, and
declared effective by, the Securities and Exchange Commission. This
press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Bolt
Biotherapeutics, Inc.
Bolt Biotherapeutics,
Inc. (“Bolt”) is a clinical-stage immuno-oncology company
developing tumor-targeted therapies that leverage the power of the
innate and adaptive immune systems. Bolt’s proprietary Boltbody™
Immune-stimulating Antibody Conjugates (ISACs) approach uses
immunostimulants to engage and activate myeloid cells that directly
kill tumor cells. This leads to the conversion of immunologically
“cold” tumors to “hot” tumors. Bolt’s lead candidate, BDC-1001, is
a Boltbody ISAC comprised of a HER2-targeting biosimilar of
trastuzumab conjugated to one of Bolt’s proprietary TLR7/8 agonists
for the treatment of patients with HER2-expressing solid tumors.
Bolt is also advancing additional Boltbody ISAC product candidates
targeting CEA and PD-L1.
Media Contacts: Maggie Beller or David
SchullRusso Partners,
LLC646-942-5631maggie.beller@russopartnersllc.com
david.schull@russopartnersllc.com
Investor Relations Contact: Sarah McCabeStern
Investor Relations, Inc.212-362-1200sarah.mccabe@sternir.com
Bolt Biotherapeutics (NASDAQ:BOLT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bolt Biotherapeutics (NASDAQ:BOLT)
Historical Stock Chart
From Sep 2023 to Sep 2024